Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 4642-4645, September 1, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kessel, D.
Right arrow Articles by Chang, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kessel, D.
Right arrow Articles by Chang, C. K.

Probing the Structure and Stability of the Tumor-localizing Derivative of Hematoporphyrin by Reductive Cleavage with LiAlH41

David Kessel2, Paul Thompson, Brian Musselman and C. K. Chang

Departments of Medicine and Pharmacology, Wayne State University School of Medicine [D. K., P. T.], Detroit, Michigan 48201, and Departments of Biochemistry [B. M.] and Chemistry [C. K. C.], Michigan State University, East Lansing, Michigan 48823

A procedure involving the use of the reducing agent lithium aluminum hydride (LiAlH4) has been designed to explore the nature of the oligomer linkages in the tumor-localizing component of hematoporphyrin derivative (HPD). High-performance liquid chromatography and fast-atom bombardment mass spectrometry were used to determine the reduction products. The results are consistent with a structure wherein ester linkages join hematoporphyrin molecules. The presence of minor amounts of ether-linked porphyrins was confirmed, and their origin was determined through the application of the chemical reduction process to HPD. An increased proportion of ether-linked porphyrins was detected during storage of HPD at room temperature or above. The commercial product Photofrin II, presumably an HPD preparation enriched in the dimcr/oligomer fraction, was found to contain approximately 50% ether link-ages. This product therefore differs from the corresponding fraction of freshly prepared HPD.

1 Supported in part by grant CA 23378 from the National Cancer Institute, NIH, Department of Health and Human Services.

2 To whom requests for reprints should be addressed at the Department of Medicine, Harper-Grace Hospitals, Detroit MI 48201.

Received 5/ 1/87. Accepted 6/ 4/87.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.